Boston-situated clinical-stage biotherapeutics company PureTech’s Phase IIb trial of deupirfenidone met all primary and secondary endpoints, slowing lung degeneration in patients with idiopathic ...
HLA Class II Expression by Hodgkin Reed-Sternberg Cells Is an Independent Prognostic Factor in Classical Hodgkin's Lymphoma Patients with stage IB-IVA MF/SS were treated with 400 mg of oral vorinostat ...
Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet its primary endpoint. The study (NCT03827798) had enrolled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback